Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01683006
Other study ID # 753/2009UH
Secondary ID
Status Completed
Phase N/A
First received April 8, 2012
Last updated August 28, 2017
Start date April 2012
Est. completion date November 2014

Study information

Verified date August 2017
Source Medical University of Vienna
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the impact of muscle relaxing drugs on the energy rate during hypothermia after cardiac arrest.


Description:

Mild hypothermia improves neurological outcome after cardiac arrest. Neuromuscular blockers are in use, together with analgesia and sedation, during the cooling process in many centers to prevent shivering. However, neuromuscular blockers are accused to be associated with various side effects causing serious harm and/or leading to prolonged ICU stay. Furthermore, the use of neuromuscular blockers may mask epileptic activity. Therefore, the advantages and disadvantages of neuromuscular blockers during therapeutic hypothermia need to be re-evaluated.

Aim of this study is to investigate if continuous application of neuromuscular blockers is necessary to prevent shivering and thereby avoiding an increase in energy expenditure in patients during therapeutic hypothermia and rewarming after cardiac arrest (initial 72h).


Recruitment information / eligibility

Status Completed
Enrollment 43
Est. completion date November 2014
Est. primary completion date May 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- All patients receiving mild therapeutic hypothermia after cardiac arrest of presumed cardiopulmonary origin

Exclusion Criteria:

- age < 18

- cardiac arrest >6 hours before admittance at the hospital

- patients with known or clinically apparent pregnancy

- patients who reach our hospital with a body temperature below 35°C

- patients with known allergic reactions against rocuronium

- patients with a history of myasthenia gravis

- patients with obvious intoxication

- wards of the state/prisoners

- patients with known epileptic disease

Study Design


Intervention

Drug:
Rocuronium
Continuous application of Rocuronium (0.5 mg/kg body weight/hour). Bolus application of placebo in case of shivering.
Placebo
Continuous application of placebo during therapeutic hypothermia. Bolus application of Rocuronium (0.5 mg/kg body weight) in case of shivering.

Locations

Country Name City State
Austria Medical University Vienna Vienna

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Other Difference in resting energy expenditure between patients with favorable and unfavorable outcome resting energy expenditure will be assessed with indirect calorimetry at different measurement time points:
12-24 h after initiation of mild hypothermia (33C°)
during warming up (at 34.5°C)
during warming up (at 36°C)
during warming up (at 36.5°C - 37.5°C)
normal Temperature, after 48 - 72 h after initiation of mild hypothermia
initial 72h after cardiac arrest at defined temperatures or timepoints: 1) 33°C 2) 34.5°C 3) 36 °C 4) 36.5 - 37.5 °C 5) after 48-72h
Other Difference in substrate metabolism between patients with favorable and unfavorable outcome substrate oxidation rates will be assessed with indirect calorimetry at different measurement time points:
12-24 h after initiation of mild hypothermia (33C°)
during warming up (at 34.5°C)
during warming up (at 36°C)
during warming up (at 36.5°C - 37.5°C)
at normal Temperature, after 48 - 72 h after initiation of mild hypothermia
initial 72h after cardiac arrest at defined temperatures or timepoints: 1) 33°C 2) 34.5°C 3) 36 °C 4) 36.5 - 37.5 °C 5) after 48-72h
Primary Change of resting energy expenditure compared to baseline at 33C° resting energy expenditure will be assessed with indirect calorimetry at different measurement time points:
12-24 h after initiation of mild hypothermia (33C°)
during warming up (at 34.5°C)
during warming up (at 36°C)
during warming up (at 36.5°C - 37.5°C)
normal Temperature, after 48 - 72 h after initiation of mild hypothermia
initial 72h after cardiac arrest at defined temperatures or timepoints: 1) 33°C 2) 34.5°C 3) 36 °C 4) 36.5 - 37.5 °C 5) after 48-72h
Secondary Change of substrate oxidation rate (protein, fat and glucose) compared to baseline at 33C° substrate oxidation rates will be assessed with indirect calorimetry at different measurement time points:
12-24 h after initiation of mild hypothermia (33C°)
during warming up (at 34.5°C)
during warming up (at 36°C)
during warming up (at 36.5°C - 37.5°C)
at normal Temperature, after 48 - 72 h after initiation of mild hypothermia
initial 72h after cardiac arrest at defined temperatures or timepoints: 1) 33°C 2) 34.5°C 3) 36 °C 4) 36.5 - 37.5 °C 5) after 48-72h
See also
  Status Clinical Trial Phase
Completed NCT04551508 - Delirium Screening 3 Methods Study
Recruiting NCT06037928 - Plasma Sodium and Sodium Administration in the ICU
Completed NCT03671447 - Enhanced Recovery After Intensive Care (ERIC) N/A
Recruiting NCT03941002 - Continuous Evaluation of Diaphragm Function N/A
Recruiting NCT04674657 - Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
Completed NCT04239209 - Effect of Intensivist Communication on Surrogate Prognosis Interpretation N/A
Completed NCT05531305 - Longitudinal Changes in Muscle Mass After Intensive Care N/A
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Completed NCT02916004 - The Use of Nociception Flexion Reflex and Pupillary Dilatation Reflex in ICU Patients. N/A
Recruiting NCT05883137 - High-flow Nasal Oxygenation for Apnoeic Oxygenation During Intubation of the Critically Ill
Completed NCT04479254 - The Impact of IC-Guided Feeding Protocol on Clinical Outcomes in Critically Ill Patients (The IC-Study) N/A
Recruiting NCT04475666 - Replacing Protein Via Enteral Nutrition in Critically Ill Patients N/A
Not yet recruiting NCT04538469 - Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Withdrawn NCT04043091 - Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction N/A
Recruiting NCT02922998 - CD64 and Antibiotics in Human Sepsis N/A
Recruiting NCT02989051 - Fluid Restriction Keeps Children Dry Phase 2/Phase 3
Completed NCT03048487 - Protein Consumption in Critically Ill Patients
Completed NCT02899208 - Can an Actigraph be Used to Predict Physical Function in Intensive Care Patients? N/A
Recruiting NCT02163109 - Oxygen Consumption in Critical Illness